CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a non-invasive prostate cancer diagnostic test that detects glycan changes on prostate specific antigen (PSA) proteins. The test aims to improve diagnostic accuracy and reduce unnecessary biopsies, providing a reliable alternative for early detection of prostate cancer.
Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually.
Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients.
The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening.
If the combined results are suspicious, the patients undergo a biopsy to confirm PCa…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
